Cited by 585Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and TreatmentAcute Lymphoblastic Leukemia research

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

Open access

Maddocks, Kami J., Ruppert, Amy S., Lozanski, Gerard, Heerema, Nyla A., Zhao, Weiqiang, Abruzzo, Lynne, Lozanski, Arletta, Davis, Melanie, Gordon, Amber, Smith, Lisa L., Mantel, Rose, Jones, Jeffrey A., Flynn, Joseph M., Jaglowski, Samantha M., Andritsos, Leslie A., Awan, Farrukh, Blum, Kristie A., Grever, Michael R., Johnson, Amy J., Byrd, John C., Woyach, Jennifer A.·2015·JAMA Oncology

DOI 10.1001/jamaoncol.2014.218PMC PMC4520535

Open this paper in CoChat — free account

Abstract

IMPORTANCE: The Bruton tyrosine kinase (BTK) inhibitor ibrutinib is effective in patients with chronic lymphocytic leukemia (CLL). Reasons for discontinuing therapy with this drug and outcomes following discontinuation have not been evaluated outside of clinical trials with relatively short follow-up. OBJECTIVE: To determine features associated with discontinuation of ibrutinib therapy and outcomes. DESIGN, SETTING, AND PARTICIPANTS: A total of 308 patients participating in 4 sequential trials of ibrutinib at The Ohio State University Comprehensive Cancer Center were included. These clinical trials accrued patients included in this analysis from May 2010 until April 2014, and data were locked in June 2014. MAIN OUTCOMES AND MEASURES: Patients were evaluated for time to therapy discontinuation, reasons for discontinuation, and survival following discontinuation. For patients who discontinued therapy because of disease progression, targeted deep sequencing was performed in samples at baseline and time of relapse. RESULTS: With a median follow-up of 20 months, 232 patients remained on therapy, 31 had discontinued because of disease progression, and 45 had discontinued for other reasons. Disease progression includes Richter's transformation (RT) or progressive CLL. Richter's transformation appeared to occur early and CLL progressions later (cumulative incidence at 12 months, 4.5% [95% CI, 2.0%-7.0%] and 0.3% [95% CI, 0%-1.0%], respectively). Median survival following RT was 3.5 months (95% CI, 0.3-6.0 months) and 17.6 months (95% CI, 4.7 months-"not reached") following CLL progression. Sequencing on peripheral blood from 8 patients with RT revealed 2 with mutations in BTK, and a lymph node sample showed no mutations in BTK or PLCG2. Deep sequencing on 11 patients with CLL progression revealed BTK or PLCG2 mutations in all. These mutations were not identified before treatment in any patient. CONCLUSIONS AND RELEVANCE: This single-institution experience with ibrutinib confirms it to be an effective therapy and identifies, for the first time, baseline factors associated with ibrutinib therapy discontinuation. Outcomes data show poor prognosis after discontinuation, especially for those patients with RT. Finally, sequencing data confirm initial reports associating mutations in BTK and PLCG2 with progression and clearly show that CLL progressions are associated with these mutations, while RT is likely not. TRIAL REGISTRATIONS: clinicaltrials.gov Identifiers:NCT01105247, NCT01217749, NCT01589302, and NCT01578707.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2014.218

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,957
Clinical staging of chronic lymphocytic leukemia
Rai, K., Sawitsky, A., Ep, C., Chanana, A. D., Levy, R., & Pasternack, B. (1975) · Blood · doi:10.1182/blood.v46.2.219.219 · Cited by 2,789
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
Self-citation
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315226 · Cited by 1,725
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
Byrd, J. C., Brown, J. R., O'Brien, S. M., Barrientos, J. C., Kay, N. E., Reddy, N. M., Coutre, S. E., Tam, C. S. L., Mulligan, S. P., Jaeger, U., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400376 · Cited by 1,665
Self-citation
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Woyach, J. A., Furman, R. R., Liu, T.-M., Ozer, H. G., Zapatka, M., Ruppert, A. S., Xue, L., Li, D. H.-H., Steggerda, S. M., Versele, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400029 · Cited by 1,275
Self-citation
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Dubovsky, J. A., Beckwith, K. A., Natarajan, G., Woyach, J. A., Jaglowski, S., Zhong, Y., Hessler, J. D., Liu, T.-M., Chang, B. Y., Larkin, K. M., et al. (2013) · Blood · doi:10.1182/blood-2013-06-507947 · Cited by 810
Self-citation
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
Herman, S. E. M., Gordon, A. L., Hertlein, E., Ramanunni, A., Zhang, X., Jaglowski, S., Flynn, J., Jones, J., Blum, K. A., Buggy, J. J., et al. (2011) · Blood · doi:10.1182/blood-2011-01-328484 · Cited by 807
Self-citation
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
Ponader, S., Chen, S.-S., Buggy, J. J., Balakrishnan, K., Gandhi, V., Wierda, W. G., Keating, M. J., O'Brien, S., Chiorazzi, N., & Burger, J. A. (2012) · Blood · doi:10.1182/blood-2011-10-386417 · Cited by 640

Flagged first, then by citations

Show all 21 references

Sorted by citations

Items 101–200 of 585

From Biology to Therapy: The CLL Success Story
Yosifov, D. Y., Wolf, C. H., Stilgenbauer, S., & Mertens, D. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000175 · Cited by 76
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial
Nastoupil, L. J., Lunning, M. A., Vose, J. M., Schreeder, M. T., Siddiqi, T., Flowers, C. R., Cohen, J. B., Burger, J. A., Wierda, W. G., O'Brien, S. M., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30216-3 · Cited by 70
Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice
Gribben, J. G., Bosch, F., Cymbalista, F., Geisler, C. H., Ghia, P., Hillmen, P., Moreno, C., & Stilgenbauer, S. (2018) · British Journal of Haematology · doi:10.1111/bjh.15080 · Cited by 70
Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway
Smith, C. I. E., & Burger, J. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.689472 · Cited by 69
Targeting Gatekeeper Mutations for Kinase Drug Discovery
Zhou, Y., Xiang, S., Yang, F., & Lu, X. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01361 · Cited by 69
Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib
Kaur, V., & Swami, A. (2017) · Annals of Hematology · doi:10.1007/s00277-017-2973-2 · Cited by 69
Critical molecular pathways in CLL therapy
Ferrer, G., & Montserrat, E. (2018) · Molecular Medicine · doi:10.1186/s10020-018-0001-1 · Cited by 68
Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations
Soumerai, J. D., Ni, A., Darif, M., Londhe, A., Xing, G., Mun, Y., Kay, N. E., Shanafelt, T. D., Rabe, K. G., Byrd, J. C., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30085-7 · Cited by 67
Self-citation
Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL
Reiff, S. D., Muhowski, E. M., Guinn, D., Lehman, A., Fabian, C. A., Cheney, C. M., Mantel, R., Smith, L., Johnson, A. J., Young, W. B., et al. (2018) · Blood · doi:10.1182/blood-2017-10-809020 · Cited by 66
Self-citation
Bruton’s tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL)
Thompson, P. A., & Burger, J. A. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1404027 · Cited by 66
Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice
Hampel, P. J., Ding, W., Call, T. G., Rabe, K. G., Kenderian, S. S., Witzig, T. E., Muchtar, E., Leis, J. F., Chanan-Khan, A. A., Koehler, A. B., et al. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1602268 · Cited by 66
Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective
Brullo, C., Villa, C., Tasso, B., Russo, E., & Spallarossa, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147641 · Cited by 65
Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated With Novel Agents
Sedlaříková, L., Petráčková, A., Papajík, T., Turcsányi, P., & Kriegová, E. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00894 · Cited by 64
Anti–BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib
McWilliams, E. M., Lucas, C. R., Chen, T. F., Harrington, B. K., Wasmuth, R., Campbell, A. R., Rogers, K. A., Cheney, C. M., Mo, X. M., Andritsos, L. A., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018025684 · Cited by 64
Self-citation
Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant
Hamasy, A., Wang, Q., Blomberg, K. E. M., Mohammad, D. K., Yu, L., Vihinen, M., Berglöf, A., & Smith, C. I. E. (2017) · Leukemia · doi:10.1038/leu.2016.153 · Cited by 62
Ublituximab ( TG ‐1101), a novel glycoengineered anti‐ CD 20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial
Sharman, J. P., Farber, C. M., Mahadevan, D., Schreeder, M. T., Brooks, H. D., Kolibaba, K. S., Fanning, S. R., Klein, L. M., Greenwald, D. R., Sportelli, P., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14447 · Cited by 63
Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial
Robak, T., Warzocha, K., Babu, G., Kulyaba, Y., Kuliczkowski, K., Abdulkadyrov, K. M., Loscertales, J., Kriachok, I., Kloczko, J. S., Rekhtman, G., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1233536 · Cited by 61
Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia
Danilov, A. V., Herbaux, C., Walter, H. S., Hillmen, P., Rule, S. A., Kio, E. A., Karlin, L., Dyer, M. J. S., Mitra, S. S., Yi, P. C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3504 · Cited by 61
How and when I do allogeneic transplant in CLL
Gribben, J. G. (2018) · Blood · doi:10.1182/blood-2018-01-785998 · Cited by 60
Targeting the B cell receptor pathway in non-Hodgkin lymphoma
Valla, K., Flowers, C. R., & Koff, J. L. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1482273 · Cited by 60
Clinical outcome and prognostic factors of patients with Richter syndrome: real‐world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC)
Abrisqueta, P., Delgado, J., Alcoceba, M., Oliveira, A. C., Loscertales, J., Hernández‐Rivas, J., Ferra, C. M., Córdoba, R., Yáñez, L., Medina, Á., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16748 · Cited by 58
Pirtobrutinib inhibits wild-type and mutant Bruton’s tyrosine kinase-mediated signaling in chronic lymphocytic leukemia
Aslan, B., Kısmalı, G., Iles, L. R., Manyam, G. C., Ayres, M., Chen, L. S., Gagea, M., Bertilaccio, M. T. S., Wierda, W. G., & Gandhi, V. V. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00675-9 · Cited by 58
Non-Covalent BTK Inhibitors—The New BTKids on the Block for B-Cell Malignancies
Lewis, K. L., & Cheah, C. Y. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080764 · Cited by 57
From identification of the BTK kinase to effective management of leukemia
Smith, C. I. E. (2016) · Oncogene · doi:10.1038/onc.2016.343 · Cited by 57
Outcomes of Richter’s transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): an analysis of the SEER database
Elnair, R. A., Ellithi, M., Kallam, A., Shostrom, V., & Bociek, R. G. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04603-y · Cited by 55
Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma–type Richter syndrome
Herrera, A. F., Ahn, K. W., Litovich, C., Chen, Y., Assal, A., Bashir, Q., Bayer, R.-L., Coleman, M., DeFilipp, Z. M., Farhadfar, N., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004865 · Cited by 56
Self-citation
Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib
Gángó, A., Alpár, D., Galik, B., Marosvári, D., Kiss, R., Fésüs, V., Aczél, D., Eyüpoglu, E., Nagy, N., Nagy, Á., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.32502 · Cited by 54
Overcoming resistance to targeted therapies in chronic lymphocytic leukemia
Skånland, S. S., & Mato, A. R. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003423 · Cited by 55
Long-term follow-up of patients with CLL treated with the selective Bruton’s tyrosine kinase inhibitor ONO/GS-4059
Walter, H. S., Jayne, S., Rule, S. A., Cartron, G., Morschhauser, F., Macip, S., Karlin, L., Jones, C. H., Herbaux, C., Quittet, P., et al. (2017) · Blood · doi:10.1182/blood-2017-02-765115 · Cited by 53
Medicinal Chemistry Strategies for the Development of Bruton’s Tyrosine Kinase Inhibitors against Resistance
Sun, S., Wu, S.-H., Kang, J.-B., Ma, Y.-Y., Chen, L., Cao, P., Chang, L., Ding, N., Xue, X., Li, N., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00030 · Cited by 54
Absence of BTK , BCL2 , and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax
Jain, N., Croner, L. J., Allan, J. N., Siddiqi, T., Tedeschi, A., Badoux, X. C. A., Eckert, K., Cheung, L. W. K., Mukherjee, A., Dean, J. P., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3934 · Cited by 53
Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment
Guo, A., Lu, P., Coffey, G., Conley, P., Pandey, A., & Wang, Y. L. (2017) · Oncotarget · doi:10.18632/oncotarget.14588 · Cited by 52
Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib
Woyach, J. A., Jones, D., Jurczak, W. J., Robak, T., Illés, Á., Kater, A. P., Ghia, P., Byrd, J. C., Seymour, J. F., Long, S., et al. (2024) · Blood · doi:10.1182/blood.2023023659 · Cited by 52
Self-citation
Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia
Giacopelli, B., Zhao, Q., Ruppert, A. S., Agyeman, A., Weigel, C., Wu, Y.-Z., Gerber, M. M., Rabe, K. G., Larson, M. C., Lu, J., et al. (2019) · Blood · doi:10.1182/blood.2019000490 · Cited by 52
Self-citation
The Phospholipase Cγ2 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein
Walliser, C., Hermkes, E., Schade, A., Wiese, S., Deinzer, J., Zapatka, M., Désiré, L., Mertens, D., Stilgenbauer, S., & Gierschik, P. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.746842 · Cited by 51
Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses
Bose, P., Gandhi, V. V., & Keating, M. J. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1239717 · Cited by 52
Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia
Puła, B., Gołoś, A., Górniak, P., & Jamroziak, K. (2019) · Cancers · doi:10.3390/cancers11121834 · Cited by 52
Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK
Dhami, K., Chakraborty, A., Gururaja, T. L., Cheung, L. W. K., Sun, C. C., DeAnda, F., & Huang, X. (2022) · Science Signaling · doi:10.1126/scisignal.abg5216 · Cited by 50
The potential of venetoclax (ABT-199) in chronic lymphocytic leukemia
Itchaki, G., & Brown, J. R. (2016) · Therapeutic Advances in Hematology · doi:10.1177/2040620716655350 · Cited by 51
How I manage ibrutinib-refractory chronic lymphocytic leukemia
Woyach, J. A. (2017) · Blood · doi:10.1182/blood-2016-09-693598 · Cited by 50
Self-citation
Efficacy and Safety of Bcl-2 Inhibitor Venetoclax in Hematological Malignancy: A Systematic Review and Meta-Analysis of Clinical Trials
Li, Q., Cheng, L., Shen, K., Jin, H., Li, H., Cheng, Y., & Ma, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00697 · Cited by 49
Ibrutinib dose modifications in the management of CLL
Hardy-Abeloos, C., Pinotti, R., & Gabrilove, J. L. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00870-w · Cited by 50
Targeting Bruton’s Tyrosine Kinase Across B-Cell Malignancies
da Cunha‐Bang, C., & Niemann, C. U. (2018) · Drugs · doi:10.1007/s40265-018-1003-6 · Cited by 47
Richter transformation in the era of novel agents
Ding, W. (2018) · Hematology · doi:10.1182/asheducation-2018.1.256 · Cited by 47
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy
Mato, A. R., Ghosh, N., Schuster, S. J., Lamanna, N., Pagel, J. M., Flinn, I. W., Barrientos, J. C., Rai, K. R., Reeves, J. A., Cheson, B. D., et al. (2020) · Blood · doi:10.1182/blood.2020007376 · Cited by 47
Richter transformation of CLL
Jain, N., & Keating, M. J. (2016) · Expert Review of Hematology · doi:10.1080/17474086.2016.1199948 · Cited by 46
Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib
Miller, C. R., Ruppert, A. S., Heerema, N. A., Maddocks, K. J., Labanowska, J. M., Breidenbach, H., Lozanski, G., Zhao, W., Gordon, A. L., Jones, J. A., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017007302 · Cited by 47
Self-citation
Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data
Isaac, K. M., & Mato, A. R. (2020) · Cancer Management and Research · doi:10.2147/cmar.s219570 · Cited by 45
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials
Jones, J. A., Mato, A. R., Coutre, S. E., Byrd, J. C., Furman, R. R., Hillmen, P., Österborg, A., Tam, C. S. L., Stilgenbauer, S., Wierda, W. G., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15421 · Cited by 46
Self-citation
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia
Kipps, T. J., Fraser, G. A. M., Coutre, S. E., Brown, J. R., Barrientos, J. C., Barr, P. M., Byrd, J. C., O'Brien, S. M., Dilhuydy, M., Hillmen, P., et al. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.07.004 · Cited by 46
Self-citation
A Germline Mutation in the C2 Domain of PLCγ2 Associated with Gain-of-Function Expands the Phenotype for PLCG2-Related Diseases
Novice, T., Kariminia, A., Del Bel, K. L., Lu, H., Sharma, M., Lim, C. J., Read, J., Lugt, M. V., Hannibal, M. C., O’Dwyer, D., et al. (2020) · Journal of Clinical Immunology · doi:10.1007/s10875-019-00731-3 · Cited by 44
Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management
Thorp, B. C., & Badoux, X. C. A. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1339874 · Cited by 44
Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies
Khan, M., Siddiqi, R. L., & Thompson, P. A. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3149-9 · Cited by 44
Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study
Davids, M. S., Kuss, B. J., Hillmen, P., Montillo, M., Moreno, C., Essell, J. H., Lamanna, N., Nagy, Z., Tam, C. S. L., Stilgenbauer, S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3061 · Cited by 44
Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting
Mhibik, M., Gaglione, E. M., Eik, D., Herrick, J., Le, J., Ahn, I. E., Chiu, C., Wielgos-Bonvallet, M., Hiemstra, I. H., Breij, E. C. W., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009517 · Cited by 43
CLL update 2022: A continuing evolution in care
Kay, N. E., Hampel, P. J., Dyke, D. L. V., & Parikh, S. A. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.100930 · Cited by 48
Current Status of Bruton’s Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies
Aw, A., & Brown, J. R. (2017) · Drugs & Aging · doi:10.1007/s40266-017-0468-4 · Cited by 43
Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples
Edwards, D. K., V, Sweeney, D. T., Ho, H., Eide, C. A., Rofelty, A., Agarwal, A., Liu, S. Q., Danilov, A. V., Lee, P., Chantry, D., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25191 · Cited by 43
Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy
Mato, A. R., Wierda, W. G., Davids, M. S., Cheson, B. D., Coutre, S. E., Choi, M. Y., Furman, R. R., Heffner, L. T., Barr, P. M., Eradat, H. A., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.207068 · Cited by 42
Self-citation
Pirtobrutinib: a new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders
Thompson, P. A., & Tam, C. (2023) · Blood Journal · doi:10.1182/blood.2023020240 · Cited by 42
A drive through cellular therapy for CLL in 2015: allogeneic cell transplantation and CARs
Mato, A. R., & Porter, D. L. (2015) · Blood · doi:10.1182/blood-2015-03-585091 · Cited by 41
Severe pneumonia associated with ibrutinib monotherapy for CLL and lymphoma
Kreiniz, N., Bejar, J., Polliack, A., & Tadmor, T. (2017) · Hematological Oncology · doi:10.1002/hon.2387 · Cited by 41
New roles for B cell receptor associated kinases: when the B cell is not the target
Nguyen, P., Niesen, E., & Hallek, M. J. (2019) · Leukemia · doi:10.1038/s41375-018-0366-8 · Cited by 41
Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections
Maffei, R., Maccaferri, M., Arletti, L., Fiorcari, S., Benatti, S., Potenza, L., Luppi, M., & Marasca, R. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100635 · Cited by 43
Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies
King, A. C., Peterson, T. J., Horvat, T. Z., Rodríguez, M., & Tang, L. A. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028016685803 · Cited by 41
Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia
Amin, N. A., Balasubramanian, S., Saiya-Cork, K., Shedden, K., Hu, N., & Malek, S. N. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2921 · Cited by 40
Inhibiting Bruton’s Tyrosine Kinase in CLL and Other B-Cell Malignancies
Lucas, F. M., & Woyach, J. A. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00635-7 · Cited by 40
Self-citation
Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia
Patel, K. K., Isufi, I., Kothari, S. K., Davidoff, A. J., Gross, C. P., & Huntington, S. F. (2020) · Blood · doi:10.1182/blood.2020004922 · Cited by 41
Guideline for the treatment of chronic lymphocytic leukaemia
Walewska, R. J., Parry‐Jones, N., Eyre, T. A., Follows, G., Martínez‐Calle, N., McCarthy, H. O., Parry, H., Patten, P., Riches, J. C., Hillmen, P., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18075 · Cited by 42
Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL
Schmidl, C., Vladimer, G. I., Rendeiro, A. F., Schnabl, S., Krausgruber, T., Taubert, C., Krall, N., Pemovska, T., Araghi, M., Snijder, B., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-018-0205-2 · Cited by 39
Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia
ten Hacken, E., Sivina, M., Kim, E., O'Brien, S. M., Wierda, W. G., Ferrajoli, A., Estrov, Z. E., Keating, M. J., Oellerich, T., Scielzo, C., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600915 · Cited by 39
FCR achieves long-term durable remissions in patients with IGHV-mutated CLL
Chai‐Adisaksopha, C., & Brown, J. R. (2017) · Blood · doi:10.1182/blood-2017-07-731588 · Cited by 39
Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and Prospects
Zhou, H., Hu, P., Yan, X., Zhang, Y., & Shi, W. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s249586 · Cited by 41
Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?
Brown, J. R., Hallek, M. J., & Pagel, J. M. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159018 · Cited by 38
Lenalidomide in the treatment of chronic lymphocytic leukemia
Itchaki, G., & Brown, J. R. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1313230 · Cited by 40
The role of 18F-FDG-PET in detecting Richter's transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor
Wang, Y., Rabe, K. G., Bold, M. S., Shi, M., Hanson, C. A., Schwager, S. M., Call, T. G., Kenderian, S. S., Muchtar, E., Hayman, S. R., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.240564 · Cited by 38
Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia
Andritsos, L. A., Grieselhuber, N. R., Anghelina, M. I., Rogers, K. A., Roychowdhury, S., Reeser, J. W., Timmers, C. D., Freud, A. G., Blachly, J. S., Lucas, D. M., et al. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1365853 · Cited by 39
Self-citation
Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study
Awan, F. T., Thirman, M. J., Patel‐Donnelly, D., Assouline, S. E., Rao, A. V., Ye, W., Hill, B. T., & Sharman, J. P. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1562180 · Cited by 37
Self-citation
Management of Ibrutinib Toxicities: a Practical Guide
Lasica, M., & Tam, C. S. L. (2020) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-020-00576-3 · Cited by 38
Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinib
Sharman, J. P., & Paolo, J. A. D. (2016) · Therapeutic Advances in Hematology · doi:10.1177/2040620716636542 · Cited by 38
Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies
Stephens, D. M., & Byrd, J. C. (2021) · Blood · doi:10.1182/blood.2020006783 · Cited by 37
Self-citation
Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment‐naïve patients with Waldenstrom macroglobulinemia
Paludo, J., Abeykoon, J. P., Kumar, S. K., Shreders, A. J., Ailawadhi, S., Gertz, M. A., Kourelis, T., King, R. L., Reeder, C. B., Leung, N., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14826 · Cited by 36
SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia
Paiva, C. J., Rowland, T., Sreekantham, B., Godbersen, C., Best, S., Kaur, P., Loriaux, M., Spurgeon, S. E. F., Danilova, O. V., & Danilov, A. V. (2017) · Haematologica · doi:10.3324/haematol.2017.170571 · Cited by 37
An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy
Cohen, J. A., Bomben, R., Pozzo, F., Tissino, E., Härzschel, A., Hartmann, T. N., Zucchetto, A., & Gattei, V. (2020) · Cancers · doi:10.3390/cancers12040894 · Cited by 37
The complex karyotype and chronic lymphocytic leukemia: prognostic value and diagnostic recommendations
Jondreville, L., Krzisch, D., Chapiro, É., & Nguyen‐Khac, F. (2020) · American Journal of Hematology · doi:10.1002/ajh.25956 · Cited by 36
Ibrutinib
Charalambous, A., Schwarzbich, M., & Witzens‐Harig, M. (2018) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-91439-8_7 · Cited by 36
Prognostic markers and standard management of chronic lymphocytic leukemia
Stilgenbauer, S. (2015) · Hematology · doi:10.1182/asheducation-2015.1.368 · Cited by 35
Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia
Hampel, P. J., Call, T. G., Rabe, K. G., Ding, W., Muchtar, E., Kenderian, S. S., Wang, Y., Leis, J. F., Witzig, T. E., Koehler, A. B., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0388 · Cited by 35
Revisiting Richter transformation in the era of novel CLL agents
Petráčková, A., Turcsányi, P., Papajík, T., & Kriegová, E. (2021) · Blood Reviews · doi:10.1016/j.blre.2021.100824 · Cited by 38
Noncatalytic Bruton's tyrosine kinase activates PLCγ2 variants mediating ibrutinib resistance in human chronic lymphocytic leukemia cells
Wist, M., Meier, L., Gutman, O., Haas, J., Endres, S., Zhou, Y., Rösler, R., Wiese, S., Stilgenbauer, S., Hobeika, E., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011946 · Cited by 34
Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model
Niemann, C. U., Mora-Jensen, H. I., Dadashian, E. L., Krantz, F., Covey, T. M., Chen, S., Chiorazzi, N., Izumi, R. E., Ulrich, R. G., Lannutti, B. J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0650 · Cited by 34
Guideline for the treatment of chronic lymphocytic leukaemia
Schuh, A., Parry‐Jones, N., Appleby, N., Bloor, A. J. C., Dearden, C. E., Fegan, C., Follows, G., Fox, C. P., Iyengar, S., Kennedy, B., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15460 · Cited by 36
Cardiotoxicity of BTK inhibitors: ibrutinib and beyond
Christensen, B. W., Zaha, V. G., & Awan, F. T. (2022) · Expert Review of Hematology · doi:10.1080/17474086.2022.2067526 · Cited by 35
Self-citation
Outcomes with ibrutinib by line of therapy and post‐ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis
O'Brien, S. M., Byrd, J. C., Hillmen, P., Coutre, S. E., Brown, J. R., Barr, P. M., Barrientos, J. C., Devereux, S., Robak, T., Reddy, N. M., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25436 · Cited by 33
Self-citation
Idelalisib for the treatment of non-Hodgkin lymphoma
Graf, S. A., & Gopal, A. K. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1135130 · Cited by 33
The STELLAR trial protocol: a prospective multicentre trial for Richter’s syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease
Appleby, N., Eyre, T. A., Cabes, M., Jackson, A. E., Boucher, R. H., Yates, F., Fox, S., Rawstron, A. C., Hillmen, P., & Schuh, A. (2019) · BMC Cancer · doi:10.1186/s12885-019-5717-y · Cited by 33
Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity
Wang, S., Mondal, S., Zhao, C., Berishaj, M., Ghanakota, P., Batlevi, C. L., Doǧan, A., Seshan, V., Abel, R., Green, M. R., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.127566 · Cited by 33
Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia
Maddocks, K. J., & Jones, J. A. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.02.008 · Cited by 32
Self-citation
Acquired platelet function disorders
Brennan, Y., Levade, M., & Wård, C. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.06.009 · Cited by 32
Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib
Alsadhan, A., Cheung, J. P., Gulrajani, M., Gaglione, E. M., Nierman, P., Hamdy, A., Izumi, R. E., Бибикова, Е., Patel, P. S., Sun, C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3505 · Cited by 32

Authors: Maddocks, K. J., Ruppert, A. S., Lozanski, G., Heerema, N. A., Zhao, W., Abruzzo, L., Lozanski, A., Davis, M., Gordon, A., Smith, L. L., Mantel, R., Jones, J. A., Flynn, J. M., Jaglowski, S. M., Andritsos, L. A., Awan, F., Blum, K. A., Grever, M. R., Johnson, A. J., Byrd, J. C., & Woyach, J. A.
Affiliations: The Ohio State University (US)
Corresponding author: Woyach, Jennifer A.
ORCID: Maddocks, Kami J.
Ruppert, Amy S.
Lozanski, Gerard
Zhao, Weiqiang
Abruzzo, Lynne
Smith, Lisa L.
Jones, Jeffrey A.
Flynn, Joseph M.
Jaglowski, Samantha M.
Andritsos, Leslie A.
Awan, Farrukh
Blum, Kristie A.
Grever, Michael R.
Johnson, Amy J.
Byrd, John C.
Woyach, Jennifer A.
Venue: JAMA Oncology
Publisher: American Medical Association (AMA)
Published: 2015-04-01
Volume: 1
Issue: 1
Pages: 80
ISSN: 2374-2437 (ISSN-L)
DOI: 10.1001/jamaoncol.2014.218
PMC: PMC4520535
OpenAlex: W1999128869
Cited by: 584
References: 21
Citations by year: 2026: 13 · 2025: 29 · 2024: 35 · 2023: 38 · 2022: 47 · 2021: 59 · 2020: 65 · 2019: 72 · 2018: 60 · 2017: 85 · 2016: 64 · 2015: 16
FWCI: 41.98
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: JAMA Oncology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (4p01ca081534-16)
National Cancer Institute (P01CA095426, U10CA180861, P50CA140158, R01CA183444, P01CA95426, K23CA178183, R01CA177292, P01-CA-081534)
Topics: Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
Keywords: chronic lymphocytic leukemia, BTK inhibitors, treatment discontinuation, Richter transformation, BTK mutations, PLCG2 mutations, relapse, deep sequencing, prognostic factors, sequential clinical trials, targeted therapy resistance
MeSH terms: Agammaglobulinaemia Tyrosine Kinase, Adenine, Adult, Aged, Aged, 80 and over, Clinical Trials as Topic, DNA Mutational Analysis, Female, Humans, Male, Middle Aged, Mutation, Ohio, Piperidines, Protein-Tyrosine Kinases, Pyrazoles, Pyrimidines, Recurrence, Risk Factors, Time Factors, Biomarkers, Tumor, Leukemia, Lymphocytic, Chronic, B-Cell, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Phospholipase C gamma, Kaplan-Meier Estimate, Molecular Targeted Therapy, High-Throughput Nucleotide Sequencing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks